Drugs / SLAMF7 FPBMC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04864522 | Aug → Nov 2023 | plasma cell myeloma | University of Virginia | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLAMF7 FPBMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04864522 ↗ |
| Modality | Cell therapy | “bispecific fresh peripheral blood mononuclear cells (FPBMC)” NCT04864522 ↗ |
| Route | Intravenous | “Patients receive 8 weekly doses and then 8 more doses every 2 weeks of SLAMF7 FPBMC by intravenous infusion.” NCT04864522 ↗ |